{"transactions":[{"id":2588825,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":135995,"kind":"person","name":"Chesworth Richard","position":1,"cik":"0001821188","reported_name":"Chesworth Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-27T16:55:43.000Z","date":"2021-08-27","kind":"exercise","acquired":false,"shares":33779,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent (25%) of the shares subject to this option vested and became exercisable on August 17, 2021, and the remainder of the shares shall vest in equal monthly installments for a period of thirty-six (36) months thereafter."}],"balance_after":263340,"derivative":{"exercise_price":20,"expiration_date":"2030-08-19","underlying":"Common Stock","underlying_shares":33779},"source":{"system":"sec-edgar","filing":"0001209191-21-053642","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821188/000120919121053642/doc4.xml","form_type":"4"}},{"id":2588824,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":135995,"kind":"person","name":"Chesworth Richard","position":1,"cik":"0001821188","reported_name":"Chesworth Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-27T16:55:43.000Z","date":"2021-08-27","kind":"sale","acquired":false,"shares":33779,"price":60.1221,"value":2030864.4159,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.99 to $60.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-053642","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821188/000120919121053642/doc4.xml","form_type":"4"}},{"id":2588823,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":135995,"kind":"person","name":"Chesworth Richard","position":1,"cik":"0001821188","reported_name":"Chesworth Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-27T16:55:43.000Z","date":"2021-08-27","kind":"exercise","acquired":true,"shares":33779,"price":20,"value":675580.0,"ownership":{"direct":true},"balance_after":33779,"source":{"system":"sec-edgar","filing":"0001209191-21-053642","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821188/000120919121053642/doc4.xml","form_type":"4"}},{"id":2596675,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":135995,"kind":"person","name":"Chesworth Richard","position":1,"cik":"0001821188","reported_name":"Chesworth Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-19T16:30:31.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":54000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Twenty-five percent (25%) of the shares subject to this option vested and became exercisable on August 17, 2021, and the remainder of the shares shall vest in equal monthly installments for a period of thirty-six (36) months thereafter."}],"balance_after":297119,"derivative":{"exercise_price":20,"expiration_date":"2030-08-19","underlying":"Common Stock","underlying_shares":54000},"source":{"system":"sec-edgar","filing":"0000899243-21-033638","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1821188/000089924321033638/doc4.xml","form_type":"4"}},{"id":2596674,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":135995,"kind":"person","name":"Chesworth Richard","position":1,"cik":"0001821188","reported_name":"Chesworth Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-19T16:30:31.000Z","date":"2021-08-17","kind":"sale","acquired":false,"shares":288,"price":52.0902,"value":15001.9776,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.06 to $52.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-033638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1821188/000089924321033638/doc4.xml","form_type":"4"}},{"id":2596673,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":135995,"kind":"person","name":"Chesworth Richard","position":1,"cik":"0001821188","reported_name":"Chesworth Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-19T16:30:31.000Z","date":"2021-08-17","kind":"sale","acquired":false,"shares":2928,"price":51.6819,"value":151324.6032,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.05 to $52.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":288,"source":{"system":"sec-edgar","filing":"0000899243-21-033638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1821188/000089924321033638/doc4.xml","form_type":"4"}},{"id":2596672,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":135995,"kind":"person","name":"Chesworth Richard","position":1,"cik":"0001821188","reported_name":"Chesworth Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-19T16:30:31.000Z","date":"2021-08-17","kind":"sale","acquired":false,"shares":41975,"price":50.3691,"value":2114242.9725,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.04 to $51.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3216,"source":{"system":"sec-edgar","filing":"0000899243-21-033638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821188/000089924321033638/doc4.xml","form_type":"4"}},{"id":2596671,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":135995,"kind":"person","name":"Chesworth Richard","position":1,"cik":"0001821188","reported_name":"Chesworth Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-19T16:30:31.000Z","date":"2021-08-17","kind":"sale","acquired":false,"shares":8809,"price":49.9049,"value":439612.2641,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.04 to $50.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":45191,"source":{"system":"sec-edgar","filing":"0000899243-21-033638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821188/000089924321033638/doc4.xml","form_type":"4"}},{"id":2596670,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":135995,"kind":"person","name":"Chesworth Richard","position":1,"cik":"0001821188","reported_name":"Chesworth Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-19T16:30:31.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":54000,"price":20,"value":1080000.0,"ownership":{"direct":true},"balance_after":54000,"source":{"system":"sec-edgar","filing":"0000899243-21-033638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821188/000089924321033638/doc4.xml","form_type":"4"}},{"id":2816142,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":135995,"kind":"person","name":"Chesworth Richard","position":1,"cik":"0001821188","reported_name":"Chesworth Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-03T16:52:27.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments over three (3) years following the Grant Date, with the first installment vesting on April 1, 2021."}],"balance_after":60000,"derivative":{"exercise_price":48.46,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-21-009410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821188/000089924321009410/doc4.xml","form_type":"4"}},{"id":3050295,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":135995,"kind":"person","name":"Chesworth Richard","position":1,"cik":"0001821188","reported_name":"Chesworth Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-21T18:28:38.000Z","date":"2020-08-20","kind":"grant","acquired":true,"shares":351119,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to this option shall vest on August 17, 2021, and the remainder of the shares shall vest in equal monthly installments for a period of thirty-six (36) months thereafter."}],"balance_after":351119,"derivative":{"exercise_price":20,"expiration_date":"2030-08-19","underlying":"Common Stock","underlying_shares":351119},"source":{"system":"sec-edgar","filing":"0000899243-20-023241","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821188/000089924320023241/doc4.xml","form_type":"4"}}]}